Keryx Pharmaceuticals' attractive pipeline, of which the two flagship products are both well into Phase III, definitely has the company and the KERX stock on many new radars lately, and the analysts are also starting to jump on board.
This month alone, both MLV Capital and Oppenheimer have initiated coverage of the company, and slapped tags of "Buy" and "Outperform" on the stock, respectively.
The newly minted analyst interest is definitely a positive indication for the company, although it's also worth pointing out that the best gains are to be had in the healthcare sector when these stocks are found before the analysts start jumping on board. By the time a company receives analyst coverage, the company has usually already realized significant gains. Case in point is KERX itself, as this stock was trading for below a buck less than two years ago.
Given that KERX has already posted significant gains, however, doesn't mean to say that there isn't any short or long term potential price appreciation left.
The two products, Zerenex for kidney disease and Perifisone as an anti-cancer agent, have both been highly successful in trials thus far, and hold significant market potential.
CLICK HERE FOR FULL ARTICLE
